A. Yuan

发表

A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.

S Shen, G L DeNardo, K. Lamborn, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung.

G. Denardo, S. Denardo, S. Shen, 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radioiodinated anti-hepatocellular carcinoma (HCC) ferritin Targeting therapy, tumor imaging and anti-antibody response in HCC patients with hepatic arterial infusion

Zhao-You Tang, Kang-da Liu, A. Yuan, 1992, Journal of Cancer Research and Clinical Oncology.

Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources.

G. Denardo, S. Denardo, S. Shen, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.

G. Denardo, S. Denardo, J. Lehmann, 2006, International journal of radiation oncology, biology, physics.

Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.

G. Denardo, S. Denardo, S. Shen, 1997, Anticancer research.

Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.

K. Lamborn, G. Denardo, S. Denardo, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Quantification of iodine-131 in tumors using a threshold based on image contrast

Shu Liao, K. Lamborn, G. Denardo, 1998, European Journal of Nuclear Medicine.

SPLENIC VOLUME CHANGE AND THERAPUETIC RESPONSE IN PATIENTS TREATED WITH RADIOMMUNOCONJUGATES

G. Denardo, S. Denardo, S. Shen, 2005 .

Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.

K. Lamborn, G. Denardo, S. Denardo, 1996, Journal of Nuclear Medicine.

Copper-2-Iminothiolane-6-[ p-( Bromoacetamido ) benzyl ]-TETA-Lym-1 for Radioimmunotherapy of Non-Hodgkin ' s Lymphoma

S. Shen, D. Kukis, A. Yuan, 2007 .

Enhancement of the Therapeutic Index: From Nonmyeloablative and Myeloablative toward Pretargeted Radioimmunotherapy for Metastatic Prostate Cancer

J. Gregg, G. Denardo, S. Denardo, 2005, Clinical Cancer Research.

Enhancement of theTherapeutic Index : FromNonmyeloablative andMyeloablative toward Pretargeted Radioimmunotherapy forMetastatic Prostate Cancer

G. Denardo, S. Denardo, H. Albrecht, 2005 .

Radioimmunotherapy with 111in/90y-2it-BAD-m170 for metastatic prostate cancer

G. Denardo, S. Denardo, S. Shen, 2001 .

Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.

F. Meyers, G. Denardo, S. Denardo, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Lym-1 for Radioimmunotherapy of Non-Hodgkin's Lymphoma

S. Shen, D. Kukis, A. Yuan, 2007 .

67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.

K. Lamborn, G. Denardo, S. Denardo, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.

G. Denardo, S. Denardo, S. Shen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Does Paclitaxel (Taxol) Given after 111In-Labeled Monoclonal Antibodies Increase Tumor-Cumulated Activity in Epithelial Cancers?

K. Lamborn, G. Denardo, S. Denardo, 2005, Clinical Cancer Research.

Combined modality radioimmunotherapy (RIT) in metastatic prostate (PC) and breast cancer (BC) using paclitaxel (PT) and a MUC-1 monoclonal antibody, m170, linked to yttrium-90 (Y-90): A phase I trial.

G. Denardo, S. Denardo, P. Lara, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selecting an intervention time for intravascular enzymatic cleavage of peptide linkers to clear radioisotope from normal tissues.

K. Lam, G. Denardo, S. Denardo, 2007, Cancer biotherapy & radiopharmaceuticals.

Dosimetrie Evaluation of Copper-64 in Copper-67-2IT-BAT-Lym-l for Radioimmunotherapy

S. Denardo, S. Shen, A. Yuan, 2006 .

Impact of splenomegaly on therapeutic response and I‐131‐LYM‐1 dosimetry in patients with B‐lymphocytic malignancies

G. Denardo, S. Denardo, S. Shen, 1997, Cancer.

The biologic window for chimeric l6 radioimmunotherapy

K. Lamborn, G. Denardo, S. Denardo, 1994, Cancer.

Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.

G. Denardo, S. Denardo, S. Shen, 2003, Cancer biotherapy & radiopharmaceuticals.

131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis.

B. Wessels, G. Denardo, S. Denardo, 2000, Cancer biotherapy & radiopharmaceuticals.

Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy.

G. Denardo, S. Denardo, S. Shen, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.

Sui Shen, Christine Hartmann-Siantar, Aina Yuan, 2005, Cancer biotherapy & radiopharmaceuticals.

High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody

K. Lamborn, G. Denardo, S. Denardo, 2005, Clinical Cancer Research.

Practical simplifications for radioimmunotherapy dosimetric models

G. Denardo, S. Denardo, S. Shen, 1999 .

Practical determination of organ S values for individual patients for therapy.

G. Denardo, S. Denardo, S. Shen, 1997, Nuclear medicine and biology.

Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.

G. Denardo, S. Shen, D. Kukis, 1999, Cancer biotherapy & radiopharmaceuticals.

Imaging and therapy of human hepatocellular carcinoma with radiolabeled monoclonal antibody

Z. Tang, YingJian Zhang, A. Yuan, 1991 .

Reproducibility of operator processing for radiation dosimetry.

K. Lamborn, G. Denardo, S. Denardo, 1997, Nuclear medicine and biology.

NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics.

R. Ivkov, G. Denardo, S. Denardo, 2008, Bioconjugate chemistry.

Imaging for improved prediction of myelotoxicity after radioimmunotherapy

G. Denardo, S. Denardo, S. Shen, 1997, Cancer.

Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, J. Lehmann, 2007, International journal of oncology.

The usefulness of99Tc-PMT delayed hepatobiliary imaging in the diagnosis of small hepatocellular carcinoma

Zeng-chen Ma, Zhao-You Tang, A. Yuan, 1992 .

Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.

G. Denardo, S. Denardo, S. Shen, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Prediction of myelotoxicity using semi-quantitative marrow image scores.

G. Denardo, S. Denardo, A. Yuan, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.